Roche Holding AG Neuroscience Update IR Event Transcript
(technical difficulty) (Operator Instructions) One last remark, if you would like to follow the presented slides on as well, please feel free to go to roche.com/investors to download the presentation. At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Thanks a lot, [Henrik.] And could I have the first slide, please?
So welcome to our fifth IR call here in 2023 and this time focusing on the Roche Neuroscience franchise. And especially, we want to focus today on the latest data presented during October at recent conferences, ECTRIMS and CTAD. So let me quickly take you through today's agenda.
We have today 3 speakers with us, 2 internal ones and 1 external. The first one is Paulo Fontoura, our Global Head of Neuroscience, Immunology, Ophthalmology, Infectors and Rare Diseases for the Clinical Development. Paulo will provide us an update on the overall Neuroscience franchise strategy. And he also will especially cover the molecules,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |